Allergan

Allergan Acquires Regenica Line With Plans To Expand Histogen Growth Factor Technology

Growth Factor-Based Skin Care

Allergan has acquired the Regenica growth factor-based skincare line, and will market the line’s proprietary multipotent cell-conditioned media, which was developed by regenerative medicine company Histogen. Allergan plans to incorporate the technology, known as Multipotent Resignaling Complex (MRCx), in future products under the SkinMedica portfolio.

Allergan CEO Questions Medical Aesthetic Treatment for Minors

Allergan CEO pushes for consensus on cosmetic treatment of minors

Allergan Chairman and CEO Brent Saunders authored a blog post from the CEO on the company’s website in which he shared his concern and discomfort with the growing number of minors undergoing cosmetic enhancement. In the post, he encouraged the medical aesthetics industry to start a dialogue on this topic in an effort to find consensus and provide guidelines for the treatment of minors. Following is Saunder’s post in full:

American Skin Association Honors Three at 30-Year Celebration

On Monday, March 27, the American Skin Association (ASA) celebrated its 30 years anniversary by presenting awards to three honorees who have made a significant impact in the areas of skin health and research. The ASA and its affiliates have funded more than $50 million in grants to support the work of more than 300 promising young scientists. In addition, the organization works to educate the public on skin health through its ASA Education Council. Monday night's honorees included:

Allergan To Acquire Zeltiq

Allergan has entered into an agreement to acquire Zeltiq Aesthetics, maker of the CoolSculpting system, for roughly $2.475 billion. The sale is expected to close in the second half of 2017. “The acquisition of Zeltiq is highly complementary and strategic to Allergan. By adding the best-in-class body contouring CoolSculpting System to our best-in-class facial aesthetics, plastic surgery and regenerative medicine offerings we are creating a world-class aesthetics business,” said Brent Saunders, chairman and CEO of Allergan.

Allergan Launches Juvéderm Volite

Allergan has launched Juvéderm Volite, a hyaluronic-based injectable filler specifically designed to improve skin quality in the face, neck, décolletage and hands. Volite uses patented Vycross technology and is formulated to last up to nine months with a single treatment session. It should be injected intradermally and contains lidocaine for patient comfort.

New Leadership on Allergan’s Board of Directors

Allergan has announced changes to leadership roles within its Board of Directors. Effective immediately, Brenton L. Saunders has been elected chairman, replacing Paul Bisaro, who served as executive chairman since July 2014. Bisaro will remain a board member. In addition to the role of Chairman, Saunders will retain his current role as president and CEO. Christopher Coughlin has also been elected lead independent director.